The Canadian Association of Pharmacy in Oncology presents the

2005 National Oncology Pharmacy Symposium
From a Patient’s Perspective
Onsite Program
2005 | Message from the Co-Chairs and Message du Comité Organisateur

On behalf of the conference organising committee, it is our pleasure to welcome you, the oncology pharmacists, to CAPhO’s annual cancer conference – the National Oncology Pharmacy Symposium (NOPS) 2005.

We are very excited to be hosting one of the first NOPS meetings outside of central Canada and what better place than in Vancouver and beautiful British Columbia. It is our intention to offer something useful, interesting – and perhaps enlightening – to all of you in this conference. As oncology pharmacists we are a diverse group of practitioners – from highly trained individuals who ply their trade in specialised areas to those of us who contribute occasional but important input into the pharmaceutical care of cancer patients. We hope that you will leave this meeting with something that you can take back with you and apply to your practice. And yes, please take this great opportunity to meet and network with your colleagues across the nation.

NOPS 2005 would not be possible without the enthusiasm and dedication of the organizing committee. We have pharmacists from across the country who volunteered their time for this conference and they have been an absolute pleasure to work with. We sincerely hope that you will have a great experience over this weekend and if so, perhaps join the committee for NOPS 2006 by contacting one of us or the CAPhO executive. Finally, we would like to thank our pharmaceutical sponsors for their generous support and invite you to visit their displays on Saturday.

True knowledge, as they say, cannot be taught, and the best teachers are the students themselves. We salute all of you who have made the effort to come to NOPS 2005 for continuing education in oncology pharmacy.

Au nom du comité organisateur, c’est avec un immense plaisir que nous vous accueillons chèr(e)s collègues pharmaciens(ne)s oeuvrant dans le domaine de l’oncologie à la conférence annuelle de l’Association Canadienne de Pharmacie en Oncologie (ACPhO) : National Oncology Pharmacy Symposium (NOPS), édition 2005.

Nous sommes heureux de vous présenter l’une des premières éditions de la conférence NOPS dans la magnifique ville de Vancouver en Colombie-Britannique. Notre objectif est de vous transmettre des connaissances utiles, enrichissantes et nouvelles. En tant que pharmaciens(ne)s oeuvrant dans le domaine de l’oncologie, nous sommes appelé(e)s à participer activement au sein de divers groupes de pratique. Et c’est dans cette optique que nous espérons que vous serez en mesure d’appliquer quotidiennement les différents sujets abordés durant ce symposium. Profitez également de cette opportunité pour rencontrer et partager vos expériences avec vos collègues pharmaciens(ne)s provenant de toutes les régions du Canada.

La réalisation du NOPS 2005 est possible, année après année, grâce à la collaboration, l’enthousiasme et le dévouement du comité organisateur et de ces différents membres qui y consacrent temps et énergie. Nous espérons sincèrement que l’expérience de cette fin de semaine vous sera profitable et sera ainsi source de motivation pour participer à l’organisation de l’édition 2006 du NOPS. Le cas échéant, contactez un des membres du présent comité organisateur ou du comité exécutif de l’ACPhO.

Nous tenons également à souligner la contribution de l’industrie pharmaceutique qui a permis la réalisation de ce symposium. Nous vous invitons, samedi prochain, à visiter les kiosques des compagnies participantes.

En conclusion, nous saluons les efforts de chacun d’entre vous qui êtes venus en grand nombre au NOPS 2005 pour parfaire votre éducation continue en oncologie.

Mario de Lemos
Victoria Kyritsis
Martin Franco
Co-Chairs
Schering Canada and Schering-Plough Corporation are dedicated to investing in cancer research both to find new uses for our existing drugs and to discover newer, even more effective therapies. We are dedicated to battling these devastating diseases.
2005 | Message from the CAphO Chair

CAphO Welcome!

On behalf of the membership of the Canadian Association of Pharmacy in Oncology and the NOPS Organizing Committee, I would like to welcome you to our annual professional meeting!

This meeting marks a change for CAphO, in that this is the first meeting to be held outside of central Canada. Last year, the CAphO Executive approved the following meeting rotation in an effort to reach even more oncology pharmacists across the country:

- 2005 Vancouver
- 2006 Montreal
- 2007 Halifax
- 2008 Toronto

The NOPS Organizing Committee has, once again, done a fabulous job, putting together one of the most comprehensive educational programs we’ve ever had. In addition, we are pleased to welcome several of our industry partners, who are sponsoring the event and the Satellite Symposia. This meeting is your chance to meet and network with your colleagues from across the country, while at the same time learning the most up-to-date oncology pharmacy information. Your CAphO Executive will also be on hand at the meeting to talk with you about the variety of initiatives that CAphO has ongoing.

We hope that you will enjoy the meeting, and look forward to seeing you there!

Lynne Nakashima
CAphO President 2003-2005

2005 | Thank you to our CAphO Executive

Lynne Nakashima
George Dranitsaris
Gabriel Gazze
Dana Cole

Susan Walisser
Tim VanHelvert
John Wiernikowski
Betty Riddell
Kim Stefaniuk

GlaxoSmithKline

Proud supporter of
CAphO & The National Oncology Pharmacy Symposium

Do more, feel better, live longer

www.gsk.ca
At Ortho Biotech we have a passion for the work we do and compassion for the patients and providers we serve.

We have dedicated our efforts to improve patient care and outcomes in cancer through treatments that enhance patients' lives.

We are committed to leading the fight against serious illness and we have engaged in comprehensive and innovative programs that benefit and empower both healthcare professionals and patients alike.
2005 | Thank you to the NOPS Planning Committee Members

Venetia Bourrier  
*CancerCare Manitoba, Winnipeg, MB*

Carole Chambers  
*Alberta Cancer Board, Calgary, AB*

Flay Charbonneau  
*Sunnybrook Regional Cancer Centre, Toronto, ON*

Mário de Lemos  
*British Columbia Cancer Agency, Vancouver, BC*

Roxanne Dobish  
*Cross Cancer Institute Pharmacy, Edmonton, AB*

Scott Edwards  
*Dr. H. Bliss Murphy Cancer Centre, St. John’s, NL*

Martin Franco  
*Hôpital Maisonneuve-Rosemont, Montréal, QC*

Victoria Kyritsis  
*British Columbia Cancer Agency, Vancouver, BC*

Sandy Linseman  
*Grand River Regional Cancer Centre, Kitchener, ON*

Kimberley Stefaniuk  
*Princess Margaret Hospital, Toronto, ON*

Pat Trozzo  
*CancerCare Manitoba, Winnipeg, MB*

Thanh Vu  
*British Columbia Cancer Agency, Vancouver, BC*

Susan Walisser  
*British Columbia Cancer Agency, Victoria, BC*
Focused research makes miracles like these happen. At Roche, we’re dedicated to trail-blazing research to create new therapies, proven diagnostics, and innovative biotechnology. Leading Canadians to a future when health threats like cancer, obesity, heart disease, stroke, and HIV truly are part of the past. Roche – Research that delivers results.
NOW AVAILABLE

Aranesp® for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies is here.

Aranesp® is indicated for the treatment of anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitantly administered chemotherapy.

Aranesp® is not intended for patients who require immediate correction of severe anemia or emergency transfusions. Blood pressure should be adequately controlled prior to initiation of Aranesp® therapy and must be closely monitored and controlled during treatment. Aranesp® is not indicated for other causes of anemia such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding which should be managed appropriately.

Aranesp® is contraindicated in patients with uncontrolled hypertension, a known hypersensitivity to the active substance or any of the excipients, sensitivity to mammalian cell-derived products or albumin formulation.

*The most commonly reported adverse events in cancer patients receiving chemotherapy were fatigue (33% vs. 30% placebo), edema (21% vs. 10% placebo), fever (19% vs. 16% placebo), dizziness (14% vs. 8% placebo), constipation (18% vs. 17% placebo), diarrhea (22% vs. 12% placebo), and arthralgia (13% vs. 6% placebo).

The most frequently reported serious adverse events included death (10%), fever (4%), pneumonia (3%), dehydration (3%), vomiting (2%), and dyspnea (2%).

Erythropoietic therapies may increase the risk of cardiovascular events, including death. The higher risk of cardiovascular events may be associated with higher hemoglobin and/or higher rates of rise of hemoglobin. The hemoglobin level should be managed carefully, with a target not exceeding 120 g/L. It is recommended that the dose of Aranesp® be decreased if the hemoglobin increase exceeds 10 g/L in any 2-week period, because of the association of excessive rate of rise of hemoglobin with these events (see Dose Adjustment).

Like all growth factors, the possibility that Aranesp® can act as a growth factor for any tumour type cannot be excluded. After a median observation period of approximately 1 year, no statistically significant differences in time-to-progression (TTP) or overall survival (OS) were observed versus placebo.

†Aranesp® is covered by Alberta Health and Wellness effective July 1, 2005 by Special Authorization. Aranesp® will be considered for Pharmacare reimbursement by Manitoba Health on an individual prescriber/patient request basis as of September 15, 2005. Aranesp® will be reimbursed as of October 5, 2005 as a médicament d’exception on the Liste de médicaments du régime général du Québec for cancer patients with anemia.

*Note: Albumin formulation not currently available in Canada.

Product Monograph available upon request.
### Schedule-at-a-glance*

#### FRIDAY, OCTOBER 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 7:30am-11:30am| OPTIMAL HEMOGLOBIN MANAGEMENT WORKSHOP  
Sponsored Pre-Conference Accredited Workshop (Ortho Biotech) |
| 11:45am-1:45pm| TREATMENT OF A CANCER-RELATED COMPLICATION IN PALLIATIVE CARE: BOWEL OBSTRUCTION  
Sponsored Pre Conference Accredited Workshop (Merck Frosst) |
| 2pm-5:30pm    | SATELLITE SYMPOSIUM  
SURVIVAL ADVANCES IN TARGETED THERAPY FOR LUNG AND COLORECTAL CANCER  
Sponsored Satellite Symposium (Roche) |
| 5:45pm-10pm   | SATELLITE SYMPOSIUM  
VELCADE (BORTezomib): AN INNOVATIVE THERAPEUTIC APPROACH IN THE TREATMENT OF MULTIPLE MYELOMA  
Sponsored Satellite Symposium (Ortho Biotech) |

#### SATURDAY, OCTOBER 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6:30am-8am    | SATELLITE SYMPOSIUM  
PREVENTING CHEMOTHERAPY INDUCED EMESIS – NEW AGENTS AND GUIDELINES  
Sponsored Satellite Symposium (Merck Frosst) |
| 7:15am-8:15am  | NOPS CONTINENTAL BREAKFAST  
(Ballrooms A & D) |
| 8:15am-8:25am  | WELCOME AND INTRODUCTION |
| 8:30am-9am    | PLENARY SESSION  
HEALTH CARE FROM THE OTHER SIDE: ONE PATIENT’S PERSPECTIVE |
| 9:05am-9:50am  | PATIENT SAFETY - THE BIG PICTURE |
| 9:55am-10:25am| ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER: WHAT IS THE STANDARD IN 2005? |
| 10:25am-10:55am| BREAK |
| 11am-11:45am  | BREATHING NEW LIFE INTO LUNG CANCER: ADJUVANT CHEMOTHERAPY |
| 11:50am-12:35pm| HANDLING CYTOTOXIC DRUGS - IS IT SAFER THAN FLYING IN A PLANE, DRIVING A CAR OR BUNGEE JUMPING? |
| 12:35pm-1:05pm| LUNCH |
| 1:05pm-2:05pm  | CAPNO ANNUAL GENERAL MEETING |
| 2:30pm-3:30pm  | BREAKOUT #A1  
DRUGGING THE HOT TARGETS - A PRIORITY OF THE IND PROGRAM AT NCIC CTG |
| 2:30pm-3:30pm  | BREAKOUT #A2  
PATIENT SAFETY WORKSHOP ON FMEA (FAILURE, MODE, EFFECTS, ANALYSIS) |
| 2:30pm-3:30pm  | BREAKOUT #A3  
| 3:35pm-4:35pm  | BREAKOUT #B1  
WORKSHOP ON MUCOSITIS MANAGEMENT |
| 3:35pm-4:35pm  | BREAKOUT #B2  
COMPATIBILITY AND STABILITY OF PARENTERAL CHEMOTHERAPY - IMPLICATIONS OF USP 797 |
| 4:35pm-6:30pm  | WINE AND CHEESE POSTER & EXHIBIT VIEWING  
(Sponsored by Schering Canada) |

#### SUNDAY, OCTOBER 30

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 7:00am-8:30am | SATELLITE SYMPOSIUM  
SUPPORTIVE CARE – GROWTH FACTORS AND THE ROLE OF THE PHARMACIST  
Sponsored Satellite Symposium (Amgen) |
| 8am-9am       | NOPS CONTINENTAL BREAKFAST |
| 9:05am-9:20am  | POSTER AWARD PRESENTATION  
(Sponsored by Schering Canada) |
| 9:25am-10:10am| TO ERR IS HUMAN, BUT DON’T BE TOO HUMAN - THE ROLE OF THE ONCOLOGY PHARMACIST IN ENSURING PATIENT SAFETY |
| 10:15am-10:45am| BREAK |
| 10:45am-11:10am| HYPERSENSITIVITY REACTIONS TO ANTI NEOPLASTIC AGENTS - TO PRE-TREAT, RE-TREAT OR NOT? |
| 11:15am-12:10pm| PANEL SESSION  
THE TEAM APPROACH; PATIENT REPRESENTATIVE/PHARMACIST WORKING TOGETHER TO RESOLVE PATIENT CONCERNS |
| 12:15pm-12:30pm| CLOSING REMARKS |
| 1pm-2:30pm    | EDUCATIONAL SESSION  
THE ROLE OF AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER IN POSTMENOPAUSAL WOMEN |
| 1pm-2:30pm    | EDUCATIONAL SESSION  
COMBINED MODALITY Therapy FOR HIGH-RISK LOCALIZED ADENOCARCINOMA OF PROSTATE |

*Please see daily schedule for room location.
Moments like these are precious.

With advances in cancer care, she can focus her energy on things that matter most. For more than a century, we have discovered some of the most important medicines that change our daily lives. Our research efforts span many spheres including cancer. Scientists at the Merck Frosst Centre for Therapeutic Research are committed to discovering today for a better tomorrow. As long as there is disease and suffering, we will continue our search.

Please visit our website at: www.merckfrosst.com
FRIDAY, OCTOBER 28 SCHEDULE

8am-11:30am
PRE-CONFERENCE WORKSHOP (Location: Parksville)
OPTIMAL HEMOGLOBIN MANAGEMENT WORKSHOP
Sponsored Pre-Conference Accredited Workshop (Ortho Biotech)
Wendy Cheung BSc(Pharm) PharmD, Pierre Y. Cremieux PhD, Sean Hopkins, Pat Trozzo BSc(Chem) BSc(Pharm)

11:45am-1:45pm
PRE-CONFERENCE WORKSHOP (Location: Port McNeil)
TREATMENT OF A CANCER-RELATED COMPLICATION IN PALLIATIVE CARE: BOWEL OBSTRUCTION
Sponsored Pre Conference Accredited Workshop (Merck Frosst)
Kim Stefaniuk, Pat Trozzo BSc(Chem) BSc(Pharm)

2pm-5:30pm
SATELLITE SYMPOSIUM (Location: Parksville)
SURVIVAL ADVANCES IN TARGETED THERAPY FOR LUNG AND COLORECTAL CANCER
Sponsored Satellite Symposium (Roche)
Dr. Janessa Laskin, Dr. Amil Shah, Flay Charbonneau

5:45pm-10pm
SATELLITE SYMPOSIUM (Location: Junior Ballroom D)
VELCADE (BORTEZOMIB): AN INNOVATIVE THERAPEUTIC APPROACH IN THE TREATMENT OF MULTIPLE MYELOMA
Sponsored Satellite Symposium (Ortho Biotech)
Dr. Lynne Nakashima, Keith Stewart MD FRCP, Gabriel Gazze BPharm DPH, Joseph Mikhael MD Med FRCP

At AstraZeneca,
we spend millions of dollars on R&D

ASTRAZENECA CANADA INC. IS PROUD TO BE A SPONSOR OF
THE 2005 NATIONAL ONCOLOGY PHARMACY SYMPOSIUM (NOPS)
every year in Canada
in our quest for new therapies and treatments.
We’re constantly seeking better ways to treat and manage
illness, to enhance patients’ quality of life,
and to keep our great healthcare system moving forward.
At AstraZeneca, that’s our commitment to healthcare.

www.astrazeneca.ca
The AstraZeneca logo is a trademark of the AstraZeneca group of companies.

AstraZeneca
life inspiring ideas
2005 | SATURDAY, OCTOBER 29 SCHEDULE

6:30am-8am
SATellite SYMposium (Location: Junior Ballrooms A & B)
PREVENTING CHEMOTHERAPY INDUCED EMESIS – NEW AGENTS AND GUIDELINES
Sponsored Satellite Symposium (Merck Frosst)
Dr. Celeste Lindley; Dr. David Warr

7:15am-8:15am
CONTINENTAL BREAKFAST FOR NOPS (Location: Grand Ballrooms A & D)

8:15am-8:25am
WELCOME AND INTRODUCTION (Location: Grand Ballrooms B & C)

8:30am-9am
PLENARY SESSION (Location: Grand Ballrooms B & C)
HEALTH CARE FROM THE OTHER SIDE: ONE PATIENT’S PERSPECTIVE
Susan R. Harris PhD PT, Professor, School of Rehabilitation Sciences, Faculty of Medicine – UBC

9:05am-9:50am
PATIENT SAFETY - THE BIG PICTURE (Location: Grand Ballrooms B & C)
Dr. Rob Robson, Director, Patient Safety, Winnipeg Regional Health Authority

9:55am-10:25am (Location: Grand Ballrooms B & C)
ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER: WHAT IS THE STANDARD IN 2005?
Sharlene Gill MD MPH FRCP, Medical Oncologist, BC Cancer Agency

10:25am-10:55am
BREAK (Location: Grand Ballrooms A & D)

11am-11:45am (Location: Grand Ballrooms B & C)
BREATHING NEW LIFE INTO LUNG CANCER: ADJUVANT CHEMOTHERAPY
Thanh Vu BSc(Pharm) PharmD, Oncology Drug Information Specialist, BC Cancer Agency

11:50am-12:35pm (Location: Grand Ballrooms B & C)
HANDLING CYTOTOXIC DRUGS - IS IT SAFER THAN FLYING IN A PLANE, DRIVING A CAR OR BUNGEE JUMPING?
George Dranitsaris MPharm FCPSHP, Consultant Pharmacist, Cancer Care Ontario

12:35pm-1:05pm
LUNCH (Location: Junior Ballrooms C & D)

1:05pm-2:05pm
CAPhO ANNUAL GENERAL MEETING (Location: Junior Ballrooms C & D)

2:30pm-3:30pm
BREAKOUT #A1 (Location: Junior Ballroom D)
DRUGGING THE HOT TARGETS - A PRIORITY OF THE IND PROGRAM AT NCIC CTG
Isabelle Gauthier PharmD, NCIC Fellow
2005 | SATURDAY, OCTOBER 29 SCHEDULE

BREAKOUT #A2 (Location: Junior Ballroom C)
PATIENT SAFETY WORKSHOP ON FMEA (FAILURE, MODE, EFFECTS, ANALYSIS)
Donna Woloschuk PharmD FCSHP MEd, Regional Pharmacy Manager (Education)
& Clinical Pharmacist – BMT, Winnipeg Regional Health Authority
2:30pm-3:30pm

BREAKOUT #A3 (Location: Junior Ballrooms A & B)
Colleen Olson BSP, Senior Pharmacist, Saskatoon Cancer Centre
3:35pm-4:35pm

BREAKOUT #B1 (Location: Junior Ballroom D)
WORKSHOP ON MUCOSITIS MANAGEMENT
Anna Granic, Pharmacist, Grand River Hospital, Kitchener, ON

BREAKOUT #B2 (Location: Junior Ballroom C)
COMPATIBILITY AND STABILITY OF PARENTERAL CHEMOTHERAPY - IMPLICATIONS OF USP 797
Scott Walker MScPhm, Coordinator, Quality Control & Research Department of Pharmacy,
Sunnybrook & Women’s Health Sciences Centre

BREAKOUT #B3 (Location: Junior Ballrooms A & B)
DRUG INTERACTION IN CHEMOTHERAPY - CYP, CYP EVERYWHERE, NOR ANY HINT OF WHAT TO DO
Carlo de Angelis PharmD, Clinical Coordinator, Pharmacy Department, Sunnybrook & Women’s Health Sciences Centre

4:35pm-6:30pm (Location: Grand Ballrooms A & D)
WINE AND CHEESE
POSTER AND EXHIBIT VIEWING
(Sponsored by Schering Canada)

Introduction to Sopherion Therapeutics Canada

Established in late 2004 in Toronto Ontario, Sopherion Therapeutics Canada Inc. commercializes oncology and oncology-related products acquired and developed by Sopherion Therapeutics. Our scientists have unsurpassed expertise and domain knowledge in the discovery, development and clinical management of oncology products with a strong emphasis in the angiogenesis and metastasis fields.

Sopherion Therapeutics first commercial product Myocet, is a liposome-encapsulated doxorubicin-citrate complex developed to reduce the cardiac toxicity associated with conventional doxorubicin. Indicated for the 1st-line treatment of metastatic breast cancer in combination with cyclophosphamide it has received regulatory approval and will soon be available in Canada.

For company and product information contact 1- 866-497-8500
Our Company’s Mission
Bristol-Myers Squibb Company’s Mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products.

Bristol-Myers Squibb Canada
2005 | SUNDAY, OCTOBER 30 SCHEDULE

6:30am-8am
SATellite SYmposium (Location: Junior Ballrooms A & B)
SUPPORTIVE CARE – GROWTH FACTORS AND THE ROLE OF THE PHARMACIST
Sponsored Satellite Symposium (Amgen)
Pat Trozzo BSc(Chem) BSc(Pharm), CancerCare Manitoba

8am-9am
CONTINENTAL BREAKFAST FOR NOPS (Location: Grand Ballrooms A & D)

9:05am-9:20am
POSTER AWARD PRESENTATION (Location: Grand Ballrooms B & C)

9:25am-10:10am (Location: Grand Ballrooms B & C)
TO ERR IS HUMAN, BUT DON’T BE TOO HUMAN - THE ROLE OF THE ONCOLOGY PHARMACIST IN ENSURING PATIENT SAFETY
Scott Edwards PharmD, Clinical Pharmacist, Newfoundland Cancer Treatment and Research Foundation

10:15am-10:45am
BREAK (Location: Grand Ballrooms A & D)

10:45am-11:10am (Location: Grand Ballrooms B & C)
HYPERSENSITIVITY REACTIONS TO ANTINEOPLASTIC AGENTS - TO PRE-TREAT, RE-TREAT OR NOT?
Carlo de Angelis PharmD, Clinical Coordinator, Pharmacy Department, Sunnybrook & Women’s Health Sciences Centre

11:15am-12:10pm
PANEL SESSION (Location: Grand Ballrooms B & C)
THE TEAM APPROACH; PATIENT REPRESENTATIVE/PHARMACIST WORKING TOGETHER TO RESOLVE PATIENT CONCERNS
Roxanne Dobish BSc(Pharm), Assistant Director of Pharmacy, Alberta Cancer Board
Pat Trozzo BSc(Chem) BSc(Pharm) BCPS, Oncology Pharmacist/Site Manager, CancerCare Manitoba
Linda Tyre, Director, Patient Representative Services Northern Alberta
Alason Lorimer RN CPNC, Patient Representative, CancerCare Manitoba

12:15pm-12:30pm
CLOSING REMARKS (Location: Grand Ballrooms B & C)

1pm-2:30pm
EDUCATIONAL SESSION (Location: Junior Ballrooms A & B)
THE ROLE OF AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER IN POSTMENOPAUSAL WOMEN
Stephen Chia, Medical Oncologist, BC Cancer Agency, Vancouver Centre, Assistant Professor of Medicine, UBC

EDUCATIONAL SESSION (Location: Junior Ballrooms A & B)
COMBINED MODALITY THERAPY FOR HIGH-RISK LOCALIZED ADENOCARCINOMA OF PROSTATE
Michael McKenzie, Radiation Oncologist, BC Cancer Agency, Vancouver Centre, Clinical Associate Professor of the Division of Radiation Oncology, UBC
2005 | NOPS SPEAKER BIOGRAPHIES

**CARLO DE ANGELIS PHARMD**
Clinical Pharmacy Coordinator – Oncology, Sunnybrook and Women’s College Health Sciences Centre; Associate Professor, Clinical Pharmacy, Faculty of Pharmacy, University of Toronto; Pharmacy Owner, Panacea Pharmacy

Carlo De Angelis received his Bachelor of Pharmacy from the University of Toronto in 1981. He did his Hospital Pharmacy Residency at Sunnybrook and Women’s College Health Sciences Centre in 1982; and he received his Doctorate of Pharmacy from the State University of New York at Buffalo in 1984. Carlo specializes in cancer treatment symptom prevention and management; education and training in Oncology Pharmacy Practice; and, practice based research to support Oncology Clinical Pharmacy activities.

**ROXANNE DOBISH | Assistant Director of Pharmacy, Alberta Cancer Board**

Roxanne has a Bachelor of Science Degree in Pharmacy from the University of Alberta. She has worked in oncology pharmacy for over 17 years in a variety of roles including staff pharmacist, involvement in the community cancer program implementation, and various management positions.

Roxanne’s areas of interest and specialization include medication error prevention, community cancer care, chemotherapy handling and certification, staff & student training, and policy and procedure development.

She is also involved in many multi-disciplinary committees and projects. Her presentation will highlight the interdisciplinary work between pharmacy and the patient representative.

**GEORGE DRANITSARIS MPHARM FCSHP | Consultant Pharmacist, Cancer Care Ontario**

George Dranitsaris is an oncology research pharmacist with graduate training in biostatistics, health economics, decision analysis and clinical epidemiology. For 8 years, he was the Coordinator of Health Economics and Outcomes Research at Ontario Cancer Institute/Princess Margaret Hospital. He is currently a consultant to the pharmaceutical industry and public health care institutions such as Health Canada and Cancer Care Ontario. His areas of interest include the measurement of cost effective drug use and quality of life in the oncology setting, clinical trial design, the development and implementation clinical practice guidelines and the application of statistical modeling techniques for the evaluation of drug use in cancer patients. He has over 30 publications in peer-reviewed journals and holds several national and international awards. He is also past president of the Canadian Association of Pharmacists in Oncology and a Fellow with the Canadian Society of Hospital Pharmacists.

**SCOTT EDWARDS PHARMD | Clinical Pharmacist, Newfoundland Cancer Treatment and Research Foundation**

Scott Edwards graduated from Memorial University of Newfoundland with a BSc (Neuroscience) in 1994 and a BSc (Pharmacy) in 1997. In 2005 he graduated with a Doctorate of Pharmacy degree from the University of Washington. Scott is currently the clinical oncology pharmacist at the Dr. H. Bliss Murphy Cancer Center, an ambulatory medical oncology clinic that services the entire province of Newfoundland and Labrador. He is actively involved with numerous duties for Memorial University School of Pharmacy. Current research interest is acting as principal investigator for a randomized control trial studying seamless care in an outpatient medical oncology clinic.
ISABELLE GAUTHIER PHARMD | NCIC Fellow

Isabelle Gauthier obtained her BSc (Pharm), and MSc from Laval University. She completed her PharmD degree followed by a specialty residency in hematology/oncology in New York. Isabelle has worked as a Clinical Professor at the University of Montreal Faculty of Pharmacy and, she also as a clinical pharmacy specialist in hemato/med oncology and the research pharmacist for the hematology/BMT team at the Ottawa Hospital.

In 2001, she joined the New Drug Development Program at the Ottawa Regional Cancer Center as the Clinical Research Coordinator. She is currently the CIHR/NCIC IND Fellow at NCIC CTG.

SHARLENE GILL BSC(PHARM) MD MPH FRCPC | British Columbia Cancer Agency, University of British Columbia

Sharlene Gill is an Assistant Professor of Medicine of Medical Oncology and an Associate Faculty Member of Gastroenterology at UBC. She received her BSc and MD from UBC followed by an Internal Medicine residency at the UBC Department of Medicine, and a Medical Oncology fellowship at the BC Cancer Agency. She completed a two-year postdoctoral clinical research fellowship in Gastrointestinal Oncology at the Mayo Clinic, and received a Master’s of Public Health in Clinical Effectiveness from the Harvard School of Public Health. Sharlene is presently a GI Medical Oncologist at the Vancouver Cancer Centre and her research interests include phase II/III clinical trials, translational research collaborations and GI cancer outcomes evaluation.

ANNE GRANIC BSC(CHEM) BSC(PHARM) | Staff Pharmacist, Grand River Hospital

Anne received a Bachelor of Science Degree in Biology from the University of Western Ontario in London, Ontario, followed by a Bachelor of Science Degree in Pharmacy at the University of Alberta in Edmonton. Anne has been working as a staff pharmacist at Grand River Hospital for 15 years. She has been involved in several clinical programs, including cardiology, general medicine and palliative care, while continuing to work in pharmacy. For the past five years her focus has been in the Oncology program and Supportive Care. The past two years she has been very busy with the Regional Cancer Centre.

SUSAN R. HARRIS PHD | Professor, School of Rehabilitation Sciences, Faculty of Medicine, University of British Columbia

Susan Harris is a Professor in the School of Rehabilitation Sciences at UBC. Having experienced breast cancer twice (in 1994 and 1998), Dr. Harris has since become involved in breast cancer rehabilitation research as well as communication issues among persons living with cancer and their health care providers. Based on her own experiences, Susan has also become an advocate for improving patient navigation through the cancer care system and enhancing interdisciplinary care. She was the recipient of the UBC Alumni Association’s Faculty Citation Community Service Award, and the Professional Achievement Award from the Canadian Breast Cancer Foundation.

ALASON LORIMER RN CPNC | Patient Representative, CancerCare Manitoba

Alason Lorimer is the Patient Representative at CancerCare Manitoba. Her role is to advocate for patients and their families throughout their cancer experience and to facilitate conflict resolution and problem solving.

She works collaboratively with all members of the care team to enhance communication between all parties. Ms. Lorimer offers an objective eye and a practical voice reducing tensions and moving people towards consensus and reconciliation. She graduated Winnipeg Health Sciences Centre School of Nursing and is a Canadian Certified Perioperative Nurse who specialized in women’s health at the Health Sciences Centre in Winnipeg for 20 years. She is currently a student at the University of Manitoba.
COLLEEN OLSON BA BSP  |  Senior Pharmacist, Saskatoon Cancer Centre

Colleen Olson graduated from the University of Saskatchewan. She currently is the Senior Pharmacist at the Saskatoon Cancer Centre. Colleen is a sectional lecturer at the College of Pharmacy at the University of Saskatchewan on Complementary and Alternative Medicine. She also is a speaker for the College of Physicians Continuing Medical Education on Herb and Complimentary Medicine.

DR. ROBERT ROBSON, DIRECTOR  |  Patient Safety, Winnipeg Regional Health Authority

Dr. Rob Robson is Chief Patient Safety Officer of the Winnipeg Regional Health Authority and is responsible for coordinating patient safety programs and initiatives throughout the region.

Dr. Robson is experienced in healthcare risk management, liability assessment, and litigation management issues and has participated in external reviews of organizations and facilities at federal, and provincial levels.

Rob has academic appointments in the Departments of Graduate Studies and Community Health Sciences of the University of Manitoba Faculty of Medicine.

Rob is a practicing specialist emergency physician. He is also a healthcare mediator and has worked for more than six years in this field.

PAT TROZZO BSC(Chem) BSc(Pharm) BCPS  |  CancerCare, Manitoba

A career pharmacist, Pat graduated with his pharmacy degree from the University of Manitoba. He is currently an oncology pharmacist with the Saint Boniface Unit of CancerCare Manitoba. He has worked in oncology for nearly 15 years, in the areas of the treatment of gastrointestinal cancers and pain and symptom management. Very active in the management of disease and treatment-related adverse effects, Pat is a member of a multi-professional pain and symptom management team. He has worked on national initiatives to promote the role of the pharmacist in providing palliative and end-of-life care. Pat is also an educator of health care professionals in this field.

The University of Manitoba, Faculty of Pharmacy, has appointed Pat clinical assistant professor in the area of oncology and pain and symptom management.

LINDA TYRE  |  Director, Patient Representative Services Northern Alberta

Linda’s nursing background lead her to human resource management and then to patient representative services. She has two levels of Patient Representative Certification from the Society of Healthcare Consumer Advocate (AHA). Linda trained in customer service, conflict resolution, negotiating skills, Volunteer Management Certification and has a certificate from U of A Facility of Extension in Adult Education.

A former member of the faculty of GMCC in Voluntary Sector Management, Linda has written a course for distant learning in this field. As the CCI Patient Representative, she has trained employees and developed courses on customer service, communication skills, and telephone edict.

Linda was the first Canadian to receive the Ruth Ravich award from SHCA/American Hospitals Association, the highest award for a Patient Representative in N. America.
THANH VU BSC PHARMD | Oncology Drug Information Specialist, British Columbia Cancer Agency

Thanh is currently the Oncology Drug Information Specialist at the BC Cancer Agency in Vancouver. She earned her undergraduate and Doctorate of Pharmacy degrees from the University of British Columbia. Thanh developed an interest in oncology early in her career, and worked at the Cross Cancer Institute in Edmonton prior to relocating to Vancouver. Thanh’s clinical interests include the management of breast and lung malignancies.

Thanh is a member of several professional societies, including the Canadian College of Clinical Pharmacy and the International Association for the Study of Lung Cancer. Thanh serves as an Expert Reviewer for the Canadian Cancer Society.

SCOTT WALKER | Coordinator of Research & Quality Control Associate Professor, Faculty of Pharmacy, University of Toronto

Scott Walker is the Coordinator of Research and Quality Control in the Department of Pharmacy at Sunnybrook & Women’s College Health Sciences Centre where he runs an analytical lab. Scott is also as an Associate Professor in the Faculty of Pharmacy at the University of Toronto where he teaches pharmacokinetics. His research interests include drug stability in support of the IV-additive program, as well as the pharmacokinetics of drugs.

A fellow of the Canadian Society of Hospital Pharmacists, Scott has received more than 30 awards in the CSHP National Award. He served as an Associate Editor of CJHP and then is now the Editor.

DONNA WOLOSCHUK PHARMD FCSHP MED
Regional Pharmacy Manager (Education) & Clinical Pharmacist – BMT, Winnipeg Regional Health Authority

Donna has practiced as an oncology/BMT pharmacy clinician for over 20 years. She holds a Doctor of Pharmacy degree, a post-doctoral Specialized Residency in Oncology/BMT, and is also a certified Adult Educator. Donna also holds an Advanced Graduate Diploma in Distance Education (Technology) as well as a Master’s Degree in Distance Education. She is an active member and Fellow of the Canadian Society of Hospital Pharmacists.

Donna's currently works for the Winnipeg Regional Health Authority which involves planning, implementing, evaluating and maintaining protocols, clinical practice guidelines and selected medication safety initiatives of the Manitoba Blood and Marrow Transplant Program and Winnipeg Regional Health Authority. She is also responsible for coordinating education and training initiatives of the WRHA’s Pharmacy Program.
2006 | National Oncology Pharmacy Symposium

Join us for NOPS 2006 in Montreal, QC
October 13 – 15, 2006
Hyatt Regency Montreal

If you are interested in joining the organizing committee please contact Martin Franco at mfranco.hmr@ssss.gouv.qc.ca

See you in 2006!